“Frontotemporal dementia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Frontotemporal dementia Understanding
Frontotemporal dementia: Overview Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer’s disease in the 45–64 age group.
"Frontotemporal dementia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal dementia.
Frontotemporal dementia Emerging Drugs Chapters This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Frontotemporal dementia Emerging Drugs • PR006: Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). Like PR001, PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9. The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD. PR006 is currently being studied in our PROCLAIM trial, a Phase I/II clinical trial of PR006 for the treatment of patients with FTD-GRN.
• AL001: Alector
AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the bloodstream to increase the levels of PGRN in the brains of FTD-GRN patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018. Currently, it is in phase III stage of development to treat Frontotemporal dementia.
Further product details are provided in the report……..
Frontotemporal dementia: Therapeutic Assessment This segment of the report provides insights about the different Frontotemporal dementia drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Frontotemporal dementia
There are approx. 20+ key companies which are developing the therapies for Frontotemporal dementia. The companies which have their Frontotemporal dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.
This report covers around 20+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Frontotemporal dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Frontotemporal dementia: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Frontotemporal dementia drugs?
• How many Frontotemporal dementia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal dementia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal dementia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Frontotemporal dementia and their status?
• What are the key designations that have been granted to the emerging drugs?
The global behavioral health software market is expected to reach USD 4.9 billion by 2026 from USD 2.0 billion in 2021, at a CAGR of 19.6% during the forecast period. The major factors driving the growth of behavioral health software are the increasing adoption of behavioral health software, availability of government funding, government initiatives...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Sleep Market Report
The sleep market by revenue is expected to grow at a CAGR of 6.11% during the period 2020–2026.
Several research studies and government programs help improve awareness explaining the importance of sleep in many countries.
The World Health Organization (WHO) made the following statement many years ago, “There is no health without mental health”.Today, as the COVID-19 pandemic ravages the world, another public health crisis is looming over our health systems—that of deteriorating mental health.
Mass unemployment, salary reductions, depleting financial...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Central Nervous System Disorders Therapeutics Market 2021-2025 The analyst has been monitoring the central nervous system disorders therapeutics market and it is poised to grow by $ 24.35 bn during 2021-2025, progressing at a CAGR of 4.44% during the forecast period. Our report on the central nervous system disorders...
175 pages •
By The Business Research Company
• May 2021
Major players in the individual and family services market are CARE International, Children’s Aid and Family Services Inc., Eastwick Family Services, Executive Healthcare Services (EHS), Feeding America, Goldfields Individual and Family Support Association (GIFSA), Kairos Family Services, North East Independent Living Services, StepStone Family...
As people learn to embrace uncertainty, the top trends outlined at the beginning of 2021 will bring about significant changes in the way societies work and live. Changes in user behavior patterns will trigger major growth opportunities influenced by changes in consumption and business models.Emerging advancements in technologies, such as AI...
190 pages •
By Global Industry Analysts
• Apr 2021
- Global Mental Health and Intellectual Disability Facilities Market to Reach $239.6 Billion by 2027
- Amid the COVID-19 crisis, the global market for Mental Health and Intellectual Disability Facilities estimated at US$172.9 Billion in the year 2020, is projected to reach a revised size of US$239.6 Billion...
Global Emerging Mental Health Devices and Platforms Market to Reach $18,717.5 Million by 2030
Market Report Coverage - Emerging Mental Health Devices and Platforms
• Product Type (Platforms and Devices)
• Application (Stress, Anxiety, Depression, Bipolar Disorder,...
This IDC Perspective discusses drastic changes in the world of work during 2020 and the challenges organizations are facing as a result. Many of these challenges are related to unpreparedness to face new realities due to the work culture; technological solutions that address such challenges were perhaps not as widely adopted or well established...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.